Table 2 Clinical trials of CD19-directed CAR-T cells in China
Target antigen | Diseases | CAR | Vector | NCT no. |
|---|---|---|---|---|
CD19 | Leukemia, lymphoma | 4-1BB- CD3ζ | RV | NCT01864889 |
CD19 | B cell malignancies | CD28, CD137, CD27 | LV | NCT03050190 |
CD19 | MCL | 4-1BB-CD3ζ | RV | NCT02081937 |
CD19 | Leukemia | NA | NA | NCT03142646 |
CD19 | B cell lymphomas | CD27-CD3ζ | LV | NCT02247609 |
CD19 | Leukemia, lymphoma | NA | NA | NCT02349698 |
CD19 | Elderly relapsed/refractory B cell ALL | NA | NA | NCT02799550 |
CD19 | Leukemia, lymphoma | NA | NA | NCT02537977 |
CD19 | B cell leukemia | NA | NA | NCT02644655 |
CD19 | B cell leukemia and lymphoma | NA | NA | NCT02813837 |
CD19 | B cell lymphoma | NA | NA | NCT02547948 |
CD19 | B cell lymphoma | CD28-CD3ζ | RV | NCT02652910 |
CD19 | Leukemia, lymphoma | CD28, CD3ζ | LV or RV | NCT02456350 |
CD19 | Recurrent or refractory acute non-T-lymphocyte leukemia | NA | NA | NCT02735291 |
CD19 | Lymphoma | NA | NA | NCT02728882 |
CD19 | Leukemia, lymphoma | NA | NA | NCT02546739 |
CD19 | B cell lymphomas | NA | NA | NCT02842138 |
CD19 | ALL | NA | NA | NCT02810223 |
CD19 | ALL | CD28-CD137-CD3ζ | LV | NCT02186860 |
CD19 | B cell leukemia, B cell lymphoma | CD3ζ, CD28, and 4-1BB | LV | NCT02963038 |
CD19 | NHL | TCRζ, 4-1BB | LV | NCT03029338 |
CD19 | B cell ALL | TCRζ, 4-1BB | LV | NCT02975687 |
CD19 | B cell leukemia and lymphoma | NA | LV | NCT02933775 |
CD19 | B cell leukemia | 4-1BB | LV | NCT02672501 |
CD19 | Central nervous system B cell acute lymphocytic leukemia | NA | NA | NCT03064269 |
CD19 | ALL | 4-1BB | LV | NCT02965092 |
CD19 | Acute leukemia | NA | NA | NCT02822326 |
CD19 | Leukemia, lymphoma | CD28 or 4-1BB and a CD3ζ | LV or RV | NCT03076437 |
CD19 | Leukemia and lymphoma | NA | NA | NCT02851589 |
CD19 | Leukemia and lymphoma | NA | NA | NCT02819583 |
CD19 | DLBCL | NA | LV | NCT02976857 |
CD19 | Recurrent or refractory B cell malignancy | NA | NA | NCT02782351 |
CD19 | Leukemia and lymphoma | TCRz-CD28, TCRz-CD137 | NA | NCT02685670 |
CD19 | B cell lymphoma | 4-1BB, CD3ζ | NA | NCT03101709 |
CD19 | ALL | NA | NA | NCT02924753 |
CD19 | ALL | NA | NA | NCT03027739 |
CD19 | B cell leukemia | NA | LV | NCT02968472 |
CD19 | B cell lymphoma | CD28ζ | NA | NCT02992834 |
CD19 | AML | NA | NA | NCT03018093 |
CD19 | Systemic lupus erythematosus | 4-1BB | LV | NCT03030976 |
CD19 | NHL | NA | LV | NCT03154775 |
CD19 | Lymphoma | NA | NA | NCT03086954 |
CD19 | ALL, CLL, lymphoma | CD28 or 4-1BB and CD3ζ | NA | NCT03191773 |
CD19 | B cell lymphoma | 4-1BB-CD28-CD3 | NA | NCT03146533 |
CD19 | Leukemia | NA | NA | NCT03173417 |
CD19 | Relapsed or refractory B cell lymphoma | 4-1BB | LV | NCT03208556 |
CD19 | B cell leukemia and lymphoma | Â | Â | NCT03166878 |
CD19 | B cell lymphoma | NA | NA | NCT03118180 |
CD19 or CD20 | Relapse/refractory B cell malignancies | NA | LV | NCT02846584 |
CD19 and CD20 | DLBCL | NA | NA | NCT02737085 |
CD19 and CD22 | Hematopoietic/lymphoid cancer | TCRζ, 4-1BB | NA | NCT02903810 |
CD19/CD20 | B cell leukemia and lymphoma | CD3ζ, 4-1BB-CD3ζ | RV | NCT03097770 |
CD19/CD22 | B cell malignancy | NA | RV | NCT03185494 |
CD19/CD22 | B cell leukemia, B cell lymphoma | NA | LV | NCT03098355 |
CD19/CD20/CD22/CD30 | B-NHL | NA | NA | NCT03196830 |
CD19/CD20 | B cell malignancy | NA | NA | NCT03207178 |
CD19 and CD20/CD22/CD38/CD123 | B cell malignancy | NA | LV | NCT03125577 |